EBS - Earnings call transcript Q2 2024 | Emergent BioSolutions Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, everyone. I'm the operator for today's call. Thank you for joining today as Emergent discusses their operational and financial results for the second quarter 2024.

As is customary, today's call is open to all participants and the call is being recorded and is copyrighted by Emergent BioSolutions.

In addition to today's press release, there is a series of slides accompanying this webcast available to all webcast participants.

X. Slide to Turning

current Emergent of circumstances. Investors their update by should projections prospects, any as the business, except forward-looking the as reports statement on forward-looking does performance. call, future expectations Emergent statements their Any date events. And information, or other of related These forward-looking their based statement are law, to future event this statements. filed evaluating as new only consider required statements beliefs, or statement cautionary may today's well and forward-looking risk undertake and regarding in call. as to factors with make speaks reflect to Emergent's forward-looking future when intentions, the not as SEC identified During events, conference their this periodic

During found today's performance. also Emergent adjustments regarding GAAP certain figures measures greater financial refer order Please may to Emergent's to non-GAAP in transparency that to press tables provide release. involve in operating today's call, discuss the

will to company, guidance, as on who the Officer, Turning Financial be Chief by the will will Lindahl, future and agenda who Rich second will followed guidance call update, Officer, Executive of President well today's comment the Q&A. Joe third to Chief for state financials as catalysts. for current including XXXX speak Papa, year quarter, for full multi-year product include highlights quarter. and This plan EVP key and X. the Slide The

then Joe? the have with would listening announcements the this was to on discussed like call that, Finally, topics XXXX. Papa August recorded for over and of webcast, Joe call. And Emergent to this now remarks. today's made for replay held opening of will may the turn I to who Since to call benefit related during those and be X,

Joseph Papa

thank Chief our today results Hello, I discuss Lindahl, Financial you by Rich our second financial today to XXXX us joined for and our Officer. and joining outlook. everyone, quarter am

guidance. then will and growth third providing our provide our as will I detail guidance for then Rich opening my year plan, quarter up summarizing for our open performance, it we'll the future well review multi-year as full quarter remarks, Following Q&A. on X thoughts drivers, our

like been enabled team early able at by our work without the Emergent I of ACAMXXXX us team specifically, executing revenue hard in our It for thanking would And a and multi-year of business. July. our mission in have guidance and especially significant great to stabilize, quarter plan effort their turn who on members efforts start this year. appreciate to to a our has First, recognize transform the I the our first half our been around were support values. we that X X team, dedication quarter exceed shipment our to

progress on X. raising adjusted of the against our great and in will to Slide Emergent. detail. guidance, through performance, on which to first-half the review stabilizing midpoint multi-year EBITDA our Rich revenue walk like focused plan I'd Based Turning our we are XXXX

our business capabilities to patients. customer-focused, to internal organization, our items future plan, and made and focused reduction improvements. and customers a as leaner, core working product capital delivered site product our more we as created for making leveraging QX debt and We and progress drivers great onetime flexible finally, streamlined support we our growth. network some against are a and our there While our well including performance in operating significant on numbers, We

plans. We our call multi-year been activities plan. stabilization like to our Slide successfully phase of during credit have Turning critical execute X. agreement, expanding the on runway our amended I'd initial the several to to that operational

XXXX. our the approximately workforce restructuring have since quarter, Camden XX% reduced transaction closes Bora by X after this May our our will site Following January combined, for announcement and we

products. from savings a We successfully have also dispute inspection settlement. million expense July, we the combined with from these Janssen completed million approximately in FDA $XX received our will Camden the payment inspection and We a the of biologic safety This highest our efforts. In commitment total underscores an great facility resolved all a full contract I these of at surveillance and standards the $XXX ensuring efforts. to again in July, is GMP our patient thank of product which quality. for team

the of calls, divesting Bora of and we through month X, have these products from a Now on in is achieved debt I'll and certain our total assets. Raise divestment Junior expected quantum Emergent's from The $XX reduce sale RSDL this proceeds XXX-person Pharmaceuticals, X transactions than Slide net in credit earning second to facility. to to the $XX to expected Camden SERB of taken reduction. Pharmaceuticals, the will satisfy Capital result year. walk this our of which more we series a discussed is strategic to quarter facility On To-date, a million amended under requirement actions our million close headcount previous

debt another by have on cash comments our that. $XX in have generated underutilized received down. Janssen at we million. anticipate Also, site million an Canton flow $XX following quarter have and sold to million related from contract Rich expect also update, warehouse We we working third our will our $X to contribute business operational million capital settlement, We and empty, year-end. dispute the $XX following for Nordic Bavarian improved pay and more to May milestone,

business product our slide to on Slide X. Turning

on commitments. Nasal highlights We NARCAN continue I'll with key around our to Spray. make the start progress delivering

to an opioid is overdose, were the X than of were caused to nearly is an a are American XXX,XXX by or in the continuing year. lost year, in crisis lives which of as crucial more expansion number unacceptable XX ever We which Spray, NARCAN opioid of This synthetic opioid. lives Last every Nasal drug than continues. invest lost more

a to more into determined in naloxone leading of life-saving convenience first help the kits hands to NARCAN, containing position points are help to continue where Canada NARCAN deaths to increase life. And get to critical save As opioid-related distribute the in product, to we the and of working are product Health people closely the we the increase, which people. are with Canada, access responders

are increase to we're areas. to awareness We across access believe impact broaden hard-hit contributing also several our and the efforts seeing

For XX% months had example, in X of suspected X,XXX from down And that's decrease Maine expected XX% Jersey an reported New in opioid-related year. XXXX, but drug deaths states deaths. the like last first overdose

NARCAN program. interest strive While of Annually, and opioid customers. individual we needed. opioid as to it's to access not about public our promising to locations expect to high see that remain the NARCAN across to serve number all deaths unfortunately, the and decreasing, expanding We Canada our NARCANDirect provider XX,XXX the of still is deaths best-in-class through deliver U.S. to we believe

now we a Nevada. faster, distribution delivery Emergent meet fact, today allows announced earlier for to center just to demand further In NARCAN for in all efficient nalaxone facility our by new This increased customers. of more having the new

[ to their ] XX,XXX have for availability websites, we access. NARCAN We right increase offering efforts. and continue an easy to delivered online To-date, our are of also barriers and through to distributed at tackle doorstep. have Amazon for pharmacy consumer workplace retailers. By way business-to-business easy enabled boxes to to creating access avenue NARCAN status we the NARCAN has OTC many the people

NARCAN, to offices NARCAN and and ordered to to a services We that which leading have a sites. their it have just Gypsum, enables few. We secured have shipped financial name X order United work NARCAN.com/Workplace, Copper, including company, businesses major States launched and businesses

and National we last this like support with educate in next the to to We places. To workplace around just Association safety. defibrillator to by new continue thread, device reach the $XX partners saved are importance their to Council lives the American businesses on each engage the Medical about public put year on Safety of and And understand defibrillators pull costs month, approximately X,XXX naloxone that average. the shared

putting each the alongside defibrillator which could measure tens to of fraction is opiate We lost a cost thousands this year. of overdose naloxone, also life-saving of lives help believe

continuous health crisis funding is and first has state Our to that access federal and country public facing responders. for bipartisan increase NARCAN helps support a

on overdoses Just in expectancy years that survey a have We study expectancy putting school these opioid XX education it to lower further life walk reported a The and to life the is those [ American high of due level be these to last burden a high of conducted, population and adults. nearly younger XX more of among by in new week, generations clearly aware year. ] to fentanyl, younger already contributed found burden deaths likely that life a less work to at effects aged were do fatal we was the naloxone here. In vulnerable reverse can Lancet risk.

respond to continue position. meet we strive need ensure to will and to our maintain to leadership our We customers'

medical our countermeasures Slide XX. to on Turning portfolio

Ebola. opioid leadership addressing anthrax, addition we including leading In health threats, public smallpox, overdose in to a and maintain position botulism epidemic,

their MCM to to million new and potential including these of We our contract of the demonstrate are runway $XXX including to modifications includes believe and This products, continued ability future reaffirm contribute milestones our also contract supply trusted VIGIV option in U.S. TEMBEXA biodefense business, totaling and $XX Ebanga optimistic growth. our as to million the the procurement. future ACAMXXXX, place over government U.S. MCM that supply to $XXX.X potential order our partner indicate CYFENDUS, for for $XX.X our a million supply million and Contracts BAT. We government with strength and total a a portfolio. about

sBLA to end Mpox approval quarter. of FDA for expect In under receive the the we fact, to from the expand by ACAM

future to levels for the to We existing second for have in pursuing of of half strong sight and the our forward procurement opportunities look awards contract a line portfolio additional year.

by announced Slide back ability decision Michigan sites services XX, work customers. Next, is streamlined bio driven deliver footprint and at to is Lansing, manufacture to in our previously our maintaining while a look our scale of products our to and This our Winnipeg. on

Rockville efforts sites, capital. our Bayview reducing our down manufacturing at winding and are working footprint and our We further

the our Canton, diverse mentioned, portfolio empty it which a sold on capabilities. In in that Slide to our review in demonstrative of abroad. I'll explore financials. and Rich we facility linked have both hand of manufacturing XX, linked continue to alternatives will network $X sites now our not are strategic to demands, Massachusetts, U.S. to summary, As our that to for efforts meet we products core expect over is to we million, our for

Richard Lindahl

good and afternoon, Joe, joining Thanks, you appreciate the call everyone. We today.

significant has progress against of As we're near-term the financial strengthening stabilizing our discussed, just and making priorities our business foundation. Joe

further momentum million a ACAMXXXX, continued million to this continue quarter influx from with submission is the announced proof Bavarian approximately points. We supplying the health XXXX. receive and CYFENDUS, facility. We travel the be our We'll Janssen which transactions, XXXX, ACAMXXXX. setting contract for commitment warehouse at into VIGIV satisfy sheet, the notification items divest we on and resulted RSDL in entered in We and a we of Our Nordic of Bora and in $XX to improving but expenses and sold triggers the value detail agreement are accepted a report billion. acceptance EMA an of sold of business sale for have up million payment year. Since definitive with anthrax also EBITDA profitability $X.XX the to announced financial provide product, going divestiture today the of vaccine, Canton sales. chikungunya the million, that first quarter. our and into U.S. government. our on requirement million we underutilized SERB chemical to for used NARCAN, our several to these million. the asset Pharmaceuticals raising balance amended facility for This annual $XXX of reinforces part expect $XXX $XXX This to reflects Emergent for announced to Pharmaceuticals $XX modifications actions overall shareholder the milestone BAT guidance July And XX. decontamination foundation international We confidential settlement received million second $XX We agreement XXXX. over can for the again completed, in Baltimore-Camden to We revenue go to facility an stronger shipments beginning that finally, received for payment the roughly midpoint solid $X delivered reduce to expected adjusted of which results million, capital credit our the will cash forward. of of $XX repayment our which Pharmaceuticals, key fully in third These once debt raise was by our

with our another results. strong our previously revenue to Turning provided above had quarter guidance. We

due for of adjusted in second and of order onetime write-down approximately As total of the U.S. of in a indicated highlights Janssen prior ACAM. $XX the and onetime in negative EBITDA segment Slide $XX year versus other margin XX% agreement, timing revenues the and year versus the XX, million, of quarter Total on million a due to related prior the the XX% $XXX year, settlement decrease U.S. versus government to timing include prior assets adjusted due the million, the to the charges primarily gross charges. procurements of quarter reduction government of

the turn we have Slide Turning a In our the and required many quarter, our number non-recurring and back, our to that slide. our to in the improve several led and site the us stabilize, A reduce impairments is future particular, related you'll reconciliation for result of business, to XX, the to asset footprint are note in evaluate taken write-offs on to are significantly here charges. our added but efforts decisions actions results turn Bioservices profitability, that of which as seen deemphasize short-term values, items in there of our shown business in part theme around non-GAAP common as the which transform tables.

order sales now legacy important and a Smallpox had versus the the of include slightly offset which international million, CYFENDUS our by decrease matters for also which MCM $X partially Slide of due sales increase delivered year, several from of mix timing. remaining move the primarily year-over-year $XX MCM demand the $XX quarter. attributed deeper continued settlement channel, RSDL product. and the volume was in ACAMXXXX, U.S. sales in driven prior robust July. overdose facility. U.S. is of million representing revenues which Other the the versus in million opioid on of of an Compared revenues, we $XX to We us. Diving to related prior NARCAN year, year, in million our ACAMXXXX $XX of second $XXX uncertainty the to behind timing ahead arbitration over-the-counter for million, decline higher by price of includes And of related interest sales. The Janssen. million, total into reflects with million, $XX public the primarily million, reversal sales to Bioservices quarterly XX $XX quarter prior resolved government timing of Bioservices a product items sales and BioThrax revenue the early unfavorable to the of NARCAN. Anthrax issues those sales of Camden procurement the The we BAT

of million, was and or million, let's adjusted gross $XXX by segment or quarter. including lower adjusted Janssen was a X XX were costs $XX driven million, of $XXX product sales was In an related of employee Slide sales $XX commercial at reflecting Cost announcement. influenced settlement MCM revenues to sale facilities. overhead those in our Bioservices, of $XX marketing-related to in And operating focused Turning XX%. comprised $XX million, expenses million, project primarily commercial up million, that, segment program. were the by spend continued by MCM entirely was segment, agreement, on by the R&D CYFENDUS product $XX margin move the costs in funded Segment Maryland quarter of termination $XX offset May million, core anthrax the sales review sales driven XX. the Slide of and and NARCAN expense million, strong ACAMXXXX. the international of quarter and associated $XX and restructuring million, includes the to of expenses. With NARCAN. the by development which decrease of are and costs the Cost performance costs restructuring segment, during Ebanga R&D asset items, costs gross on currently XX%. write-down of margin SG&A BioThrax. In Outside our the offset revenues Cost with

adjusted million, negative services was now segment million. I'll and the margin gross summarize moment as for were $XX a take $XX year-to-date performance segment, XXXX XX. to our shown Slide As revenues on

MCM by First first roughly costs well or half MCM and EBITDA up $XX sales as million, was reflecting Year-to-date an million, versus Bioservices. was was the to versus $XXX adjusted prior as $XXX improvement million prior XX% driven million, reduce $XXX timing, year. gross revenue year, margin and our XX%, of prior half efforts

a $XX quarter with as cash million our roughly June the of revolving debt And reduction ended in Net to total XXXX, under to a capital XX. working capital optimize our credit and improvement than capital of at free second quarter. XX, million $XX including net up liquidity, facility. availability position million was the quarter $XXX and first continuing $XX We Turning Slide million the We million, working to June million versus XX, position quarter, prior lower on XXXX. million remain $XX was focused $XXX versus the debt repayment. second for our $XX of

see please XX. guidance, Slide XXXX to Turning

improve to significant we operating immediately, happen making will While our performance progress. efforts not are

our for XXXX. this evening, As the release full outlook in press our we're announced updating year

did the and on of and we guidance. appendix. Total million Slide adjusted as revenue Commercial in shown both we revenues midpoint product billion. to billion Full XX year details EBITDA the raising $X.XX sales as $XXX $XXX guidance to in revenue For profitability, is $X.XXX of our May, are of the and million. are follows

now have versus to XXXX. million impact our of forecasting We're has impact as for operating adjusted for metrics. second adjusted million CYFENDUS, $XXX million Having million. the well due for sale We of visibility not this that facility guidance million received sales that, which May strong our channels. environment. yet last at X, closed. EBITDA $XX EBITDA of public demand Having a we're is taking continue the to Camden product but see a the revenue our the of Services revenues of increase improved midpoint Since as the MCM interest, on competitive our BAT million note currently we profitability our OTC in our $XX the on guidance that yet million developments the the transaction and to It's revenue there million half VIGIV. of MCM ACAM, the that, on report prior of given related a RSDL, in important sale, million, and to we $XXX $XXX reflects $XXX of XXXX $XXX of Canadian for as last reflects Janssen negative to the revenue to award $X upcoming more million. in of continued reflect segment does of to large said conservative and NARCAN $XXX million U.S. We view MCM committed forecast an settlement. Shifting focus to increase year. not week, completed Camden expenses. The said $XX the to $XXX portion to

full forecasting the of XXXX, segment we're the For final turn financial to to quarter, to XX% total million. That's adjusted all we're to revenue range Shifting of back for the forecasting I'll now year XX%. in for a margin call Joe the over $XXX million gross update. $XXX thoughts. of third some

Joseph Papa

you, Thank Rich.

operational at impact position to Our Emergent made our But hardworking on changes and the progress we forward, potential is strategic our Emergent team drivers well around look meaningful growth position have the for world. see the lives opportunities future. turnaround. we stabilize to executing us that significant This to for financial as critical the

unique time. transformation past that on expansion and and focus of over in-line public pleased focus Turning importantly, take for funding paydown of to partnerships current will strategic But the and debt has not organization address our like the capabilities that potential increased closing, leverage look epidemic. In or progress the -- the to #XX, month, that and It's international linear. we our achieved. team preparedness made health expansion said, public-private and opioid willingness our will growth I'm our products. This to Slide the created with value our on the future health have the own I'd partnership, identify our drivers line products, extensions like on based

year are paying for prepare the to strong amount exciting down up our of to turnaround We out planning an finish debt operator, questions. that, by phase line a move significant additional let's towards the we future. With open enter while and

Operator

be Instructions] of coming Fye question from Jessica Our will JPMorgan. [Operator

Elias Lenard

This is Jess. Nick on for

well you and peak across maybe, distribution opportunity there? overall Kind NARCAN with do future about both to Nevada, current with in you long-term the And growth could the and how comment First, PIP in thinking you kind growth for talk capabilities of on as the new NARCAN you expand What are opportunity market sales potential market? about as can of driver for the the OTC decision as PIP? OTC NARCAN? see the center

Joseph Papa

Sure.

Paul, I'm help who's Paul feel a Williams, joined can add questions. to us to is address got questions there. also here, This of Papa. Joe You lot these start. by in. free who I'll

and big got there progress shown think that available markets. help foremost, in about and most a the solved health to that states believe it. and think, amount solve some it's the settlements terms get the in public got number We've of to to is the from from real will solve this we're problem make things. Number to to market I go this first category, has also some what to public we've interest believe access solving good excited all expand drug and it. We NARCAN NARCAN, is still XXX,XXX continue We United pharma this. amount year, of talking I'd States ability to to the program, point by we more that that will last in ability towards in still a X% the The will our of fact NARCAN when of more the of #X, companies that deaths. but was means help educational do purchase reduction into that the but there's come you're a remaining to their opioid about deaths going total to funding lot expand the that a

I think items the us. for and first big one of it's foremost

very many into allow be to all clearly states. to NARCAN our markets, a these are Beyond of to programs going believe to are those and very that, and closely working that's us, important we the with that provider interest we believe, public of NARCANDirect states embedded we continue

clearly probably question? other add answer brand to part But add. believe that So that things the I a foremost you of would Paul, are want important is those to We first the it. think and very I itself things

Paul Williams

think access think, allow around well with really can over-the-counter, Drug naloxone. as us, And Joe, Maybe, don't of into White couple recently in is One those we Office Control as a going you and in the Discussion, coming emphasis I out Naloxone think I of is, long National Policy House. businesses. the I we're understate of on of where And address and see think things. understanding the overdose, the the through I a we've and which Roundtable Yes. retail to before to barely too to continue we've to the actually attended level all about starting -- drive demand NARCAN, awareness online of And and a is expand got but start We've to the XXX,XXX states. go by to we got just way shelves the Obviously, decrease a solve poisoning, way to that accidental expanding in one, started addiction we're around fentanyl deaths deaths, for space. point market seeing talking much. before to that, plateau

Joseph Papa

bipartisan by not of And think support that epidemic And we for believe there's out year, difference. do what this because problem. population almost have opioid. make solving than saying that's of comment I States reducing any but the today. overall about now. in further is on we get bipartisan says, for the look issue volumes important the a think that I that just there impact to Lancet we a solving can about I support, the one, That United I NARCAN part has have can week opioid-related death article Paul have opioid life we real came U.S. an just the And to of volumes important see live you is right world the how mean, this it. But I a think why often a expectancy is out ago support the of one and is, we bipartisan in says doesn't think

today. just help we're So Nevada we with the announced going responsive, is and the It more to be a I to capabilities which is distribution more the think customer-focused we create has distribution makes center our to -- us that that allows do flexibility. added that's leaner, faster growth. We for what believe organization clearly future, and what's customer why trying us

all a the think why being NARCAN I are for future. opportunity reason So great we those as the see things

Elias Lenard

mind, with distribution a contemplating months for are Great. California the OTC you seeing to current other in outlook And with State that And you agreement your are your states? with few other OTC that a supply NARCAN. announced back, trends the product? of any competitor How amongst

Joseph Papa

Sure. be We're importance some still reduction opioid California with closely. very to has of support that. obviously very we closely which work very targets, We of California working clear. aggressive the the State

California. We one-stop-shop continue again, makes products of Nevada the for supply access products. it them to essentially it a that, as to in we a easier And of to the getting us to deliver I center State said having before, make we also state believe our distribution the California. for to the NARCANDirect Once easier to program is embedded have into public because service process for

capabilities with States going are manufacturing believe locations believe work our why So, the United believe important. to like with we to And California, with the the continue work just State is distribution XX,XXX the capability and very We we capacity is brand to NARCAN We important. all we're our of important states. reasons around we're other going be going our of we to market are as in expands, fair we're expansion we of well. get to as states try this successful that well. but We're leader. that terms access. total overall improve for we're of market with that's how share the as other California, to believe the continue And to State the approaching And going

Elias Lenard

see color on steps you're some taking of And maybe provide for to some on additional some maybe margin the margins business? profile you provide improve achievable and current an Great. as the detail could what long-term you

Joseph Papa

just you business, I asking specifically total understand the... about NARCAN Are so or just

Elias Lenard

if Total want -- NARCAN comment total to you specifically. that well, but as business, on

Joseph Papa

with questions me let Yes. where of are. your that's NARCAN, start bases the because Well,

We our partners of cost continuing sold to total are our our reduce and of clearly working work with contract to product. goods on the for manufacturing the product

we already and understanding this have year. good can a do have of made We some progress what we

targeted look But the what's cost closely expect cetera. we're vehicles actual the assembly, We progress the then for at working of very in et by even -- and material, more nasal cost is device the future. to those where the to and specific raw also for the for we've cost the terms what's

for to at all down avenues that NARCAN bring cost. Looking

I to of terms is margin, our of business, rest in us the network reductions our cost gross more of you site. doing, as comments. our sold creating at want just looking some Rich, site. at think the in will I probably efficient give think more leaner, may things But a we one of just manufacturing we're on significant each make that become goods believe efficient overall We

will As gross we're during shut more, Lansing to help steps way Rockville, relative Winnipeg those down margin efficient more each time. go And get we site, action remaining improvement. to going -- us sell the important Camden as about savings and we'll the the the the site all we talked site the think mostly forward. believe, become obviously remaining are divest that's site, the Canton with Bayview we Obviously, the we're much I to we site, those over as our shutting as going overall we we down call, believe

Richard Lindahl

less end capacity the really of network. the network through we come think cost I major right. think capacity helping so terms we cost taken sold we've manufacturing have That's And the out are the the of to very -- Yes, really next forward. excess unutilized as goods disciplined year. or that our SG&A, into is site driver so I in of come And in that's that of year. again we overall our we SG&A level will year into flow and then which very And year next R&D as we're this about through of we spending this the as being finally, working hard out go reduce on then, side,

Elias Lenard

and Okay. one the on from for should Maybe color you just TEMBEXA an us some we when then. provide Ebanga? last Could option expect

Joseph Papa

today, have that United and hard On of option and continuity options are continue the the into the of by next of on with really to out as anything few So conversations or, TEMBEXA, about to the magnitude have several I exercise. of of maintain to still forward. nature I that the followed we that. don't we procurement working development We future, had think we a States Government product on should Ebanga, say, the years is years which scale the timing supply up, commercialization following but contract, move based report

Operator

showing [Operator would now no Instructions] back I'm like further closing turn questions. remarks. Joe to I for the to call

Joseph Papa

again, you today. thank us everyone, Well, for joining

to work all As the at to for I the the team our milestones quarter us onset, we've great like help Emergent to the achieve I'd achieved. during thank mentioned

the of half second the the improvement. paydown course, to for our by finishing capital to working to paydown, year and strong, forward debt continue look debt reduce already operational we're the performance of improve to we business then, continuing adding that that the Importantly, overall importantly, and debt

be We everyone. day, important things any and those Have our go to look Thank parts we all all out will So future. as chance talk a to of additional great questions of have forward you. to a you.

Operator

will page ladies forward version call Thank and you again. in archived PDF Please company's today's that, with of you your with call. you, an Investors a We well for be all. gentlemen, slides as Goodbye. website. the all you during note, speaking version today's later And to the available of the we participation. today look landing future. the webcast now through Thank the used as accessible and Thank conclude on

Emergent BioSolutions (EBS) 6 Aug 242024 Q2 Earnings call transcript